NCT06176729RecruitingPhase 2
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
A Prospective Phase II Study of Polatuzumab, Rituximab, and Lenalidomide(Pola-R2) in Newly-diagnosed Non-fit Elderly DLBCL Patients
Source: ClinicalTrials.gov · Last updated 20 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 5 Dec 2023
- Start date
- 24 Oct 2023
- Primary completion date
- 24 Oct 2025
- Lead sponsor
- Yan Zhang, MD
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT06176729
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 24 Oct 2023 to the primary completion date, 24 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Coexisting malignancy other than lymphoma
- Active HBV infection
- Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy
Who the study is looking for
- The patient volunteered to participate in the study and signed the Informed Consent
- Histopathologically confirmed DLBCL and treatment naive(corticosteroids alone is not considered as a line of treatment)
- Age≥ 70 years old, and was un-fit or frail according to comprehensive geriatric assessment
- Adequate organ function and adequate bone marrow reserve
Age in the registry: 70 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.